Omega Diagnostics Group plc
("Omega" or "the Group" or "the Company")
Investor Presentation
Omega Diagnostics Group plc (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that Colin King, Chief Executive, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.
The event will be held on Monday, 5 October 2020 at 2pm. To access the event, please register your interest at https://voxmarkets.brand.live/c/omega-diagnostics-investor-presentation
No new price-sensitive information is disclosed as part of the presentation. Within the presentation the Company provides indicative guidance on timelines for product evaluations, product supply, potential timing for first commercial sales and targeted production volumes. These timelines are for guidance purposes only and there is no guarantee that these will be met. The Company expects to keep shareholders updated regularly on progress in achieving these future milestones.
For further information, please contact:
|
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
|
|
Colin King, Chief Executive |
||
|
Kieron Harbinson, Group Finance Director |
||
|
finnCap Ltd |
Tel: 020 7220 0500 |
|
|
Geoff Nash / Teddy Whiley (Corporate Finance) |
||
|
Alice Lane (ECM) |
||
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
|
|
Paul McManus |
Mob: 07980 541 893 |
|
|
Lianne Cawthorne |
Mob: 07584 391 303 |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.